IDD-AN-A1

IDD-AN-A1 (2.5-100 μg/mL; 10 min) potently inhibits purified Mtb ICL with an IC₅₀ of 7 μg/mL via concentration-dependent inhibition^[1].
IDD-AN-A1 (6.25-100 μg/mL; 7 days) exhibits potent anti-tuberculosis activity against drug-sensitive Mtb H37Rv with an MIC of 6.25-12.5 μg/mL, but is inactive against drug-resistant Mtb strains^[1].
IDD-AN-A1 (0.78-50 μg/mL; 7 days + 24 h) exhibits additive activity with Rifampicin (HY-B0272) and synergistic activity with Delamanid (HY-10846) against Mtb H37Rv^[1].
IDD-AN-A1 (0.39-200 μg/mL; 24 h) has a favorable safety profile against RAW 264.7 cells, with a selectivity index of 32 and a CC₅₀ of >200 μg/mL^[1].
IDD-AN-A1 (2×-4×MIC; 48 h) inhibits intracellular growth of Mtb in RAW 264.7 macrophages, reducing infection by 34% at 2× MIC and 50% at 4× MIC^[1].
IDD-AN-A1 (2×-8×MIC; 21 days) exerts time-dependent bacteriostatic activity against Mtb H37Rv, maintaining reduced viability over 21 days at 2× MIC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.